Archer Materials (ASX:AXE) said it was granted a US patent for its biochip project, representing the design and work done on the development of the biosensing chip for graphene complexes and their compositions that can be used in biomolecular sensing, according to a Wednesday Australian bourse filing.
It has been researching new methods to attach inorganic molecules to graphene, a form of carbon.
The firm considers the US a critical strategic jurisdiction to protect and potentially commercialize its biochip intellectual property.
The firm's executive chair, Greg English, said that the US is a key market "due to the size of the market and the rate of chronic kidney disease in the country."
The firm's shares rose almost 11% in recent trading on Wednesday.